Fibrosis in IBD: from pathogenesis to therapeutic targets

BackgroundIntestinal fibrosis resulting in stricture formation and obstruction in Crohn's disease (CD) and increased wall stiffness leading to symptoms in ulcerative colitis (UC) is among the largest unmet needs in inflammatory bowel disease (IBD). Fibrosis is caused by a multifactorial and complex process involving immune and non-immune cells, their soluble mediators and exposure to luminal contents, such as microbiota and environmental factors. To date, no antifibrotic therapy is available. Some progress has been made in creating consensus definitions and measurements to quantify stricture morphology for clinical practice and trials, but approaches to determine the degree of fibrosis within a stricture are still lacking.ObjectiveWe herein describe the current state of stricture pathogenesis, measuring tools and clinical trial endpoints development.DesignData presented and discussed in this review derive from the past and recent literature and the authors' own research and experience.Results and conclusionsSignificant progress has been made in better understanding the pathogenesis of fibrosis, but additional studies and preclinical developments are needed to define specific therapeutic targets.